Skip to main content

Table 1 Side effects in combination therapy at the point of sacrifice.

From: Modulating effect of the PI3-kinase inhibitor LY294002 on cisplatin in human pancreatic cancer cells

  Control Cisplatin (5 mg/kg) LY294002 (25 mg/kg) Cisplatin (5 mg/kg) + LY294002 (25 mg/kg)
Body weight (g) 23.7 ± 0.8 23.6 ± 0.5 23.8 ± 0.7 23.7 ± 0.8
Serum albumin (g/dl) 3.2 ± 0.2 3.1 ± 0.2 3.1 ± 0.3 3.2 ± 0.2
Total bilirubin (mg/dl) 0.04 ± 0.02 0.05 ± 0.01 0.06 ± 0.01 0.04 ± 0.02
Creatinine (mg/dl) 0.05 ± 0.02 0.06 ± 0.02 0.08 ± 0.02 0.05 ± 0.03
ALT (IU/l) 34.1 ± 9.7 31.5 ± 5.6 30.0 ± 6.7 44.1 ± 9.7 *
  1. This table shows the body weights and serum albumin, total bilirubin, and creatinine levels at the end of therapy on day 28 in vivo experiments. No significant side effects were detected except for a slight elevation of ALT level in the combination therapy group. Values represent the means (± SD) of n = 7. P < 0.05 compared with LY294002 treatment group.